Shiraishi T, Shirakusa T, Iwasaki A, Hiratsuka M, Yamamoto S, Kawahara K
Second Department of Surgery, Fukuoka University School of Medicine, 7-45-1 Nanakuma, Fukuoka City, Fukuoka 814-0180, Japan.
Surg Endosc. 2004 Nov;18(11):1657-62. doi: 10.1007/s00464-003-9269-4.
We investigated the feasibility and suitability of video-assisted thoracoscopic surgery (VATS) segmentectomy for curing selected non-small cell lung cancer (NSCLC) with this less invasive technique.
We performed VATS segmentectomy for small (< 20 mm) peripherally located tumors and pathologically confirmed lobar lymph node-negative disease by frozen-section examination during surgery. Of the 34 patients who underwent this limited resection, 22 were treated with complete hilar and mediastinal lymph node dissection (intentional group), whereas 12 patients who were deemed to be high risk in their toleration for lobectomy underwent VATS segmentectomy with incomplete hilar and mediastinal lymph node dissection (compromised group). The surgical and clinical parameters were evaluated and compared with those of segmentectomy under standard thoracotomy to evaluate the technical feasibility of VATS segmentectomy.
We found that VATS segmentectomy could be performed safely with a nil mortality rate and acceptably low morbidity. The mean period of observation was relatively short at 656.7 +/- 572.1 and 783.4 +/- 535.8 days in the intentional and compromised groups, respectively. At the time of writing, all intentional patients remain alive and free of recurrence. There were two cases of non-cancer-related death in the compromised group. Clinical data indicated that VATS segmentectomy caused the same number or fewer surgical insults compared with segmentectomy under standard thoracotomy.
The present results are intermediate only; the rate of long-term survival and the advantages of the less invasive procedure still need further investigation. Nevertheless, we believe that VATS segmentectomy with complete lymph node dissection is a reasonable treatment option for selected patients with small peripheral NSCLC.
我们采用这种侵入性较小的技术,研究了电视辅助胸腔镜手术(VATS)肺段切除术治疗特定非小细胞肺癌(NSCLC)的可行性和适用性。
我们对小的(<20mm)周围型肿瘤进行VATS肺段切除术,并在手术中通过冰冻切片检查进行病理证实的叶淋巴结阴性疾病。在接受这种有限切除的34例患者中,22例接受了完整的肺门和纵隔淋巴结清扫(意向组),而12例被认为肺叶切除耐受性高风险的患者接受了VATS肺段切除术,肺门和纵隔淋巴结清扫不完整(妥协组)。评估手术和临床参数,并与标准开胸肺段切除术的参数进行比较,以评估VATS肺段切除术的技术可行性。
我们发现VATS肺段切除术可以安全进行,死亡率为零,发病率低至可接受。意向组和妥协组的平均观察期相对较短,分别为656.7±572.1天和783.4±535.8天。在撰写本文时,所有意向组患者均存活且无复发。妥协组有2例与癌症无关的死亡。临床数据表明,与标准开胸肺段切除术相比,VATS肺段切除术造成的手术损伤数量相同或更少。
目前的结果仅为中期结果;长期生存率和这种侵入性较小手术的优势仍需进一步研究。然而,我们认为,对于选定的小的周围型NSCLC患者,VATS肺段切除术联合完整淋巴结清扫是一种合理的治疗选择。